Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? (Q38272551)

1 September 2017

1 reference

title

Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? (English)

1 reference

1 September 2017

Marc-Andre Cornier

1

1 reference

PubMed ID

25432858

1 September 2017

Robert H Eckel

series ordinal

2

1 reference

1 September 2017

1 January 2015

1 reference

Current Atherosclerosis Reports

1 September 2017

1 reference

1 September 2017

17

1 reference

1 September 2017

475

1 reference

1 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-014-0475-4

1 September 2017

0 references

cites work

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

A comprehensive description of muscle symptoms associated with lipid-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Outcomes in 45 patients with statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Statin-drug interactions: not a class effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Idiosyncratic drug-induced liver injury: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Statins and cognitive function: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

An assessment by the Statin Cognitive Safety Task Force: 2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Cognitive impairment associated with atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Statins and neuroprotection: a prescription to move the field forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Discontinuation of statins in routine care settings: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Alternate-day dosing with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Effect of coenzyme q10 on myopathic symptoms in patients treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Efficacy of alternate-day dosing versus daily dosing of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0475-4

Statins induce differentiation and cell death in neurons and astroglia

21 January 2018

1 reference

12 December 2020

Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature

1 reference

12 December 2020

Dietary intake of naturally occurring plant sterols is related to a lower risk of a first myocardial infarction in men but not in women in northern Sweden

1 reference

12 December 2020

Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes

1 reference

12 December 2020

Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).

1 reference

12 December 2020

Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle

1 reference

12 December 2020

Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement

1 reference

12 December 2020

Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

N-of-1 (single-patient) trials for statin-related myalgia.

1 reference

12 December 2020

Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity

1 reference

12 December 2020

Effects of once weekly rosuvastatin among patients with a prior statin intolerance

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers

1 reference

12 December 2020

10.1007/S11883-014-0475-4

Identifiers

DOI

1 reference

PubMed ID

25432858

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25432858